SIDE EFFECTS Short term side effects after administration include: Facial flushing Reduced appetite, nausea and vomiting In males, spontaneous erections 1-5 hours after administration (priapism), associated with yawning and stretching complex Long term, there is concern that melanotan II may increase the risk of: Melanoma a potentially serious form of skin cancer Deepening of the color of moles, new moles and atypical melanocytic naevi Melanonychia brown to black discoloration of one or more nails Suggested usage: daily for 1 - 2 weeks then one to two times weekly for maintenance
Black Hairy Tongue Black hairy tongue is a benign, acquired condition affecting the dorsal tongue characterized by darkly discolored, elongated filiform papillae
No guns
Facilitating the process of laying eyelashes on the shield Reduces procedure time due to ease of use Perfect presentation No need to use lash film, which allows the laminating composition to freely penetrate into the hollows of the hairs No worries of gluing the upper and lower eyelashes together Nourish and moisturize eyelashes thanks to coconut ,olive and jojoba oils and vitamin E Witch hazel extract softens the hairs and gives the product an additional astringent property
group III: 3 points (RR: 85-1269) (Figure 3).3,15,30 Thus, the presence of dysplastic nevi and AMS can be considered as a spectrum of phenotypic expressions, which confers to the carriers different risks of developing melanoma.3,21 The risk spectrum varies from individuals with sporadic dysplastic nevi, with no personal or family history of melanoma, to the opposite extreme with AMS individuals belonging to families in which two or more members had melanoma, forming the so-called familial atypical multiple-mole melanoma syndrome (FAMMM).3,4,15,16,20,31 Besides presenting an increased risk of developing cutaneous melanoma, AMS patients tend to present neoplasia in unusual sites (such as the scalp) at an earlier age than the non-carriers of the syndrome.1 There is also increased risk for multiple melanomas and non-cutaneous melanoma in those patients, such as ocular melanoma.8 Prospective studies show that the risk of melanoma in members of families affected by AMS and FAMMM is significant, with an estimated cumulative risk of 49% in individuals 10 to 50 years of age and 82% in individuals 72 years of age.32 Histopathology Although the histopathologic exam is considered to be the gold standard for the diagnosis of melanocytic tumors, there are limitations in the histologic distinction between early melanomas and dysplastic nevi.12 In several studies, the reproducibility in grading the atypia remains poor to moderate, due to a lack of uniform criteria among dermatopathologists.12,18 Based on the World Health Organization (WHO) and NIH consensus, the histopathologic diagnosis of dysplastic nevi (Figure 4) is based on the major criteria (mandatory) and minor criteria (at least two must be present)23, detailed in Table 2
